Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clonitazene is a synthetic opioid analgesic belonging to the benzimidazole class of compounds known as nitazenes. It acts primarily as a mu-opioid receptor agonist and produces analgesic effects comparable to or slightly less potent than morphine in animal models. Clonitazene was developed in the mid-20th century but was never marketed due to its high potential for abuse and risk of respiratory depression. It is classified as an experimental and illicit substance with no accepted medical use. Clonitazene is structurally related to other nitazenes such as etonitazene and metonitazene, which are generally more potent[2][3][7]. The drug has been detected in illicit drug markets and is controlled under Schedule I regulations in several countries due to its abuse potential[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonitazene.